ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Cardiovascular Risk in CKD Pregnancy: Contraindicated — statins inhibit cholesterol synthesis critical for fetal development. Stop immediately if pregnancy confirmed.

Atorvastatin (CKD Cardiovascular Risk)

Brand names: Lipitor

Adult dose

Dose: 10-80 mg once daily (in the evening for maximal effect during overnight cholesterol synthesis)
Route: Oral
Frequency: Once daily (evening preferred)
Max: 80 mg/day
HMG-CoA reductase inhibitor. SHARP trial demonstrated benefit in CKD. No dose adjustment required in CKD — atorvastatin is hepatically metabolised (CYP3A4). In dialysis-dependent patients without prior statin use: no new benefit demonstrated (AURORA, 4D trials for dialysis-specific populations).

Paediatric dose

Route: Oral
Seek specialist opinion — licensed from age 10 for familial hypercholesterolaemia only

Dose adjustments

Renal

No dose adjustment required — hepatically metabolised. Safe in all stages of CKD including on haemodialysis. However, do NOT initiate atorvastatin in patients already on haemodialysis without prior statin use — no outcome benefit in this population (AURORA trial).

Hepatic

Contraindicated in active liver disease or unexplained persistent LFT elevation. Use with caution in any hepatic impairment.

Clinical pearls

  • SHARP trial (Baigent et al. Lancet 2011): simvastatin 20 mg + ezetimibe 10 mg vs placebo in 9,270 CKD patients — 17% relative risk reduction in major atherosclerotic events; benefit in non-dialysis CKD. NICE recommends statin for all CKD patients.
  • AURORA trial (Fellstrom et al. NEJM 2009): rosuvastatin vs placebo in haemodialysis patients — NO reduction in cardiovascular events despite LDL lowering. This counterintuitive result suggests uraemic CV disease is driven by non-LDL mechanisms (inflammation, calcification) not responsive to statins.
  • Implication: START statins in CKD BEFORE dialysis (pre-dialysis CKD benefits per SHARP). Patients already on statins when starting dialysis should CONTINUE. But initiating a new statin in a dialysis patient without prior cardiovascular indication has uncertain benefit.
  • Ciclosporin interaction: in transplant patients on ciclosporin, atorvastatin AUC increases 8-fold. Pravastatin or fluvastatin preferred in transplant patients (less CYP3A4 interaction).
  • Rhabdomyolysis risk factors in CKD: CKD itself (reduced statin clearance at higher doses), interacting drugs, hypothyroidism (screen before starting), family history of myopathy. Check CK at baseline and if symptoms develop.

Contraindications

  • Active liver disease
  • Unexplained persistent elevated transaminases
  • Myopathy
  • Concomitant strong CYP3A4 inhibitors increasing rhabdomyolysis risk (clarithromycin, itraconazole, HIV PIs)
  • Pregnancy and breastfeeding

Side effects

  • Myopathy/rhabdomyolysis (rare — higher risk at 80 mg or with interacting drugs)
  • Elevated transaminases (check LFTs at baseline and 3 months)
  • New-onset diabetes (small increased risk — class effect)
  • Headache
  • GI upset

Interactions

  • Strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV PIs, ciclosporin) — dramatically increase atorvastatin AUC; rhabdomyolysis risk. Use lowest dose or alternative statin (pravastatin/rosuvastatin — not CYP3A4).
  • Colchicine — additive myopathy risk; use caution in CKD
  • Gemfibrozil — additive myopathy; avoid combination
  • Ciclosporin — 8-fold increase in atorvastatin AUC; limit to 10 mg/day

Monitoring

  • LFTs at baseline and 3 months after initiation or dose change
  • CK (at baseline and if myalgias develop)
  • Lipid profile (fasting) at 3 months then annually
  • Blood glucose (new-onset DM monitoring)

Reference: BNFc; BNF 90; SHARP Trial (Baigent et al. Lancet 2011); AURORA Trial (Fellstrom et al. NEJM 2009); NICE NG203 (CKD); NICE NG136; SPC Lipitor. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways